Burden of Illness of Alpha- and Beta-Thalassemia: A Qualitative Study
Sujit Sheth(Columbia University Irving Medical Center), Kevin H.M. Kuo(University Health Network), Cristina Abel, Keely Gilroy(Agios Pharmaceuticals (United States)), Alexander Glaros(Central Michigan University), William R. Lenderking(Ithaka Harbors), Mona L. Martin, Susan Morris(Agios Pharmaceuticals (United States))
Cited by 2
Related Papers
ISOQOL recommends minimum standards for patient-reported outcome measures used in patient-centered outcomes and comparative effectiveness research
|Quality of Life Research|2013|855
A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia
|New England Journal of Medicine|2020|320
Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study
|Blood|2018|165
Safety and Efficacy of Mitapivat in Pyruvate Kinase Deficiency
|New England Journal of Medicine|2019|162